Anti-Ulcer drug shows promise for arthritis relief

NCT ID NCT05166304

Completed Disease control Sponsor: October 6 University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether rebamipide, a drug normally used for stomach ulcers, can help control rheumatoid arthritis when added to standard methotrexate therapy. Sixty adults with active arthritis took either rebamipide or a placebo three times daily. Researchers measured joint pain, swelling, and disability to see if the drug improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rebamipide (an anti-ulcer drug) taken as 100 mg tablets three times daily
What this could lead to: If it works, this could offer a new, affordable add-on treatment to better control rheumatoid arthritis symptoms.
What could go wrong: This is a small, early-phase trial (Phase 1/2) with only 60 participants, so results may not apply broadly. Rebamipide is not a standard arthritis drug, and its benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Minia University

Minya, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.